Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Strong leadership key to embracing innovations and digital transformation in healthcare industry, says GlobalData

The healthcare industry is undergoing constant changes resulting from a range of issues from declining profit margins to stringent regulatory and legislative requirements. Against this backdrop, strong leaders, who can provide clear directions and an effective roadmap, are essential to a complete digital transformation process and ride the next wave of innovation, says GlobalData, a […]
Read more

Lack of skills and talents top factor hindering digital transformation efforts in healthcare industry, finds GlobalData

A successful digital transformation often requires thorough planning, adequate funding, talents, and organizational adaptability. However, the COVID-19 pandemic acted as a catalyst for the healthcare industry and forced many companies to ramp up their digital transformation efforts without proper planning in place, says GlobalData. The leading data and analytics company notes that this fast-tracked digital […]
Read more

Insilico Medicine-Sanofi deal: artificial intelligence is making its way into drug discovery and development, says GlobalData

Following the news that Insilico Medicine has signed a billion-dollar, multi-target artificial intelligence (AI) drug discovery deal with Sanofi; Urte Jakimaviciute, Senior Director of Market Research at GlobalData, offers her view: “Sanofi is among a number of companies that are quite aggressively tapping into AI-based drug development deals. In November 2021, it invested $180 million […]
Read more

Inflation and rising costs to slow down digital transformation initiatives in healthcare sector, finds GlobalData survey

A total of 58% healthcare industry professionals globally believe that digital transformation initiatives—involving the implementation of emerging technologies such as artificial intelligence (AI), big data, cloud computing, application programming interfaces (API) and others—would be slowed down due to inflation and rising costs, according to a survey by GlobalData, a leading data and analytics company. The […]
Read more

New entrants can alter aHUS digital landscape in Japan, says GlobalData

Atypical hemolytic uremic syndrome (aHUS) is an extremely rare chronic genetic disease with very limited treatment options in Japan. Against this backdrop, the entry of new treatments such as pharmaceutical giants Novartis and Roche that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says GlobalData, a leading data and analytics […]
Read more

China COVID-19 drugs pipeline focuses on new variants amidst rising concerns of zero-COVID policy, says GlobalData

COVID-19 resurgence in China is a great concern globally due to the presence of two new Omicron sub-variants—BF.7 and BA.5.1.7, as they are highly infectious with greater transmissibility. As a result, the country has reinforced emphasis on its zero-COVID policy. Against this backdrop, Chinese companies COVID-19 drugs pipeline focus on new variants, observes GlobalData, a […]
Read more

Actinium’s Iomab-B is likely to address key unmet need in AML patient group after positive pivotal trial results, says GlobalData

Following the news that the Phase III pivotal SIERRA trial investigating Actinium’s targeted therapy Iomab-B (iodine i 131 apamistamab) in patients aged 55 years or older with relapsed or refractory acute myeloid leukemia (r/r AML), met its primary endpoint of durable complete remission (dCR) of 6 months post initial remission after a bone marrow transplant (BMT); […]
Read more

Accessibility challenges associated with mAbs in Japan likely to limit uptake of next-generation drugs for Alzheimer’s, says GlobalData

Monoclonal antibodies (mAbs), which are emerging as promising disease-modifying treatments for Alzheimer’s disease (AD), come with significant challenges associated with their accessibility. The technology to identify the pathological features of AD and safe administration of mAb therapies currently limit their access globally, with Japan being no exception. While the positive top-line results from Clarity AD, […]
Read more

SAR-bisPSMA theranostic from Australia’s Clarity may prove to be cost-effective to treat prostate cancer, says GlobalData

Clarity Pharmaceuticals, an Australia-based clinical-stage radiopharmaceutical company, has successfully recruited and treated its first patient in the Phase I/II theranostic trial evaluating 64Cu/67Cu SAR-bisPSMA theranostic product in patients with metastatic, castration-resistant prostate cancer (mCRPC). SAR-bisPSMA is a next-generation platform that uses inexpensive copper-67 radioisotopes. As a result, it may prove to be cost effective, giving […]
Read more

Contract injectable drug dose manufacturing revenues rise sharply but unsustainably as demand for vaccines falls, says GlobalData

As a result of the COVID-19 pandemic, demand significantly increased for the manufacture of sterile injectable drugs, due to the extensive outsourcing of vaccine production and insufficient capacity worldwide for the scale required, says GlobalData. According to the leading data and analytics company, revenues from companies that were contract manufacturing injectable drugs grew at unsustainable […]
Read more

Minerva’s schizophrenia treatment roluperidone faces many hurdles before FDA approval, says GlobalData

Minerva Neurosciences receiving a refusal to file letter from the Food and Drug Administration (FDA) regarding its new drug application for roluperidone for the treatment of negative symptoms in patients with schizophrenia is yet another obstacle to roluperidone’s development, says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Schizophrenia Market Size and […]
Read more

AV-101 gains competitive lead over TNX-201 as first potential imatinib therapy for pulmonary arterial hypertension, says GlobalData

Tenax Therapeutics’ announcement of a delay in its Phase III trial for its oral imatinib drug, TNX-201, in the treatment of pulmonary arterial hypertension (PAH), has pushed its main competitor Aerovate Therapeutics further into the lead with its inhaled imatinib drug, AV-101, according to GlobalData, a leading data and analytics company. Kaya Olczak, Healthcare Analyst […]
Read more

Powder-based formulations for migraine treatments may struggle to compete with oral products, says GlobalData

Due to the growing popularity of new competing therapies for acute migraine treatment, novel reformulations of dihydroergotamine (DHE) such as Satsuma Pharmaceutical’s lead product STS101 and Pulmatrix’s PUR3100, which are both powder-based formulations, may struggle to find a competitive edge over oral gepants and oral ditans, says GlobalData, a leading data and analytics company. Christie Wong, Pharma Analyst at […]
Read more

Autism spectrum disorder cases are fluctuating globally due to lack of consistent diagnostic criteria between countries, says GlobalData

Trends in the growth of autism spectrum disorder (ASD) cases are inconsistent worldwide, according to research by GlobalData, with countries such as the US seeing an increase in cases, while Japan and countries in Europe experience negative growth. The leading data and analytics company notes that this fluctuation may be due to a lack of […]
Read more
1 … 41 42 43 44 45 … 108